On June 21, June 24 and June 30, PhRMA and RDPAC, together with EFPIA, JPMA and BIO, co-hosted the annual Joint China Strategy Sessions on Science/Regulatory, Intellectual Property and Market Access. Over 125 attendees joined each of the virtual sessions, where representatives and outside speakers provided updates and perspectives on key issues and the associations presented their joint policy priorities and proposed advocacy plans for the coming year. Participants were particularly interested in topics such as China’s human genetic resource requirements and regulatory data protection (which have regulatory and intellectual property implications), recent developments with patent term linkage/adjustment/extension, and our joint NRDL project, as well as commercial health insurance.
On behalf of RDPAC and PhRMA, we would like to express our sincere thanks the cooperation and support from all participants. Special thanks to Hong Chow(Roche), Julio Gay-Ger(Lilly), Ingrid Zhang(Novartis), Michael Lai(AstraZeneca), Chen Siyuan(BMS), Wei Zhang(BI), Janet Lu(Roche), Frank Zhu(Roche), Kent Yang(Novartis), Cathy Qian(Pfizer), for your active participation in the 2021 Joint China Strategy Sessions. The discussions that took place and the input we received are invaluable for our collective efforts to advance our priorities. We appreciate the time and consideration you spent to prepare and share your insights.
As a next step, PhRMA and RDPAC will work together to develop summaries and finalize action plans that incorporate member feedbacks from the sessions.
